Kumar B Rajan1, Robert S Wilson2, Jennifer Weuve2, Lisa L Barnes2, Denis A Evans2. 1. From the Department of Internal Medicine, Rush Institute for Healthy Aging (K.B.R., J.W., D.A.E.), Rush Alzheimer Disease Center (R.S.W., L.L.B.), and Departments of Neurological Sciences (R.S.W., L.L.B.) and Behavioral Sciences (R.S.W., L.L.B.), Rush University Medical Center, Chicago, IL. kumar_rajan@rush.edu. 2. From the Department of Internal Medicine, Rush Institute for Healthy Aging (K.B.R., J.W., D.A.E.), Rush Alzheimer Disease Center (R.S.W., L.L.B.), and Departments of Neurological Sciences (R.S.W., L.L.B.) and Behavioral Sciences (R.S.W., L.L.B.), Rush University Medical Center, Chicago, IL.
Abstract
OBJECTIVE: To examine the relation of performance on brief cognitive tests to development of clinically diagnosed Alzheimer disease (AD) dementia over the following 18 years in a sample of African Americans and European Americans. METHODS: A composite cognitive test score based on tests of episodic memory, executive function, and global cognition was constructed in a prospective population-based sample of 2,125 participants (55% African American and 61% female) aged 65 years and older residing in 4 Chicago neighborhoods. Time before AD dementia diagnosis was categorized into 6 groups corresponding to data collection periods: 0.1-0.9, 1.0-3.9, 4.0-6.9, 7.0-9.9, 10.0-12.9, and 13.0-17.9 years. RESULTS: Of 2,125 participants without clinical AD dementia, 442 (21%) developed clinical AD dementia over 18 years of follow-up. Lower composite cognitive test scores were associated with the development of AD dementia over the duration of the study. The magnitude of association between composite cognitive test score and development of AD dementia increased from an odds ratio of 3.39 (95% confidence interval 1.72, 6.67; p < 0.001) at 13.0-17.9 years to 9.84 (95% confidence interval 7.41, 13.06; p < 0.001) at 0.1-0.9 years, per SD increment. These associations were consistently larger among European Americans than among African Americans. Performance on individual cognitive tests of episodic memory, executive function, and global cognition also significantly predicted the development of AD dementia, with associations exhibiting a similar trend over 18 years. CONCLUSIONS: Our findings suggest that cognitive impairment may manifest in the preclinical phase of AD dementia substantially earlier than previously established.
OBJECTIVE: To examine the relation of performance on brief cognitive tests to development of clinically diagnosed Alzheimer disease (AD) dementia over the following 18 years in a sample of African Americans and European Americans. METHODS: A composite cognitive test score based on tests of episodic memory, executive function, and global cognition was constructed in a prospective population-based sample of 2,125 participants (55% African American and 61% female) aged 65 years and older residing in 4 Chicago neighborhoods. Time before AD dementia diagnosis was categorized into 6 groups corresponding to data collection periods: 0.1-0.9, 1.0-3.9, 4.0-6.9, 7.0-9.9, 10.0-12.9, and 13.0-17.9 years. RESULTS: Of 2,125 participants without clinical AD dementia, 442 (21%) developed clinical AD dementia over 18 years of follow-up. Lower composite cognitive test scores were associated with the development of AD dementia over the duration of the study. The magnitude of association between composite cognitive test score and development of AD dementia increased from an odds ratio of 3.39 (95% confidence interval 1.72, 6.67; p < 0.001) at 13.0-17.9 years to 9.84 (95% confidence interval 7.41, 13.06; p < 0.001) at 0.1-0.9 years, per SD increment. These associations were consistently larger among European Americans than among African Americans. Performance on individual cognitive tests of episodic memory, executive function, and global cognition also significantly predicted the development of AD dementia, with associations exhibiting a similar trend over 18 years. CONCLUSIONS: Our findings suggest that cognitive impairment may manifest in the preclinical phase of AD dementia substantially earlier than previously established.
Authors: Jennifer J Manly; Diane M Jacobs; Pegah Touradji; Scott A Small; Yaakov Stern Journal: J Int Neuropsychol Soc Date: 2002-03 Impact factor: 2.892
Authors: R S Wilson; D A Bennett; J L Bienias; N T Aggarwal; C F Mendes De Leon; M C Morris; J A Schneider; D A Evans Journal: Neurology Date: 2002-12-24 Impact factor: 9.910
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: C H Kawas; M M Corrada; R Brookmeyer; A Morrison; S M Resnick; A B Zonderman; D Arenberg Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: C R Jack; R C Petersen; Y Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E G Tangalos; E Kokmen Journal: Neurology Date: 2000-08-22 Impact factor: 9.910
Authors: Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider Journal: Arch Neurol Date: 2003-02
Authors: Julia L Bienias; Laurel A Beckett; David A Bennett; Robert S Wilson; Denis A Evans Journal: J Alzheimers Dis Date: 2003-10 Impact factor: 4.472
Authors: Andrea R Zammit; Charles B Hall; Richard B Lipton; Mindy J Katz; Graciela Muniz-Terrera Journal: J Int Neuropsychol Soc Date: 2018-01-10 Impact factor: 2.892
Authors: Kumar B Rajan; Robert S Wilson; Lisa L Barnes; Neelum T Aggarwal; Jennifer Weuve; Denis A Evans Journal: J Gerontol A Biol Sci Med Sci Date: 2017-03-01 Impact factor: 6.053
Authors: Annie M Racine; Rebecca L Koscik; Sara E Berman; Christopher R Nicholas; Lindsay R Clark; Ozioma C Okonkwo; Howard A Rowley; Sanjay Asthana; Barbara B Bendlin; Kaj Blennow; Henrik Zetterberg; Carey E Gleason; Cynthia M Carlsson; Sterling C Johnson Journal: Brain Date: 2016-06-20 Impact factor: 13.501
Authors: Kumar B Rajan; Lisa L Barnes; Robert S Wilson; Jennifer Weuve; Elizabeth A McAninch; Denis A Evans Journal: J Am Geriatr Soc Date: 2018-12-24 Impact factor: 5.562
Authors: Ge Li; Eric B Larson; Jane B Shofer; Paul K Crane; Laura E Gibbons; Wayne McCormick; James D Bowen; Mary Lou Thompson Journal: J Am Geriatr Soc Date: 2017-09-21 Impact factor: 5.562
Authors: Julien Dumurgier; Bernard J Hanseeuw; Frances B Hatling; Kelly A Judge; Aaron P Schultz; Jasmeer P Chhatwal; Deborah Blacker; Reisa A Sperling; Keith A Johnson; Bradley T Hyman; Teresa Gómez-Isla Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: L C Bratzke; R L Koscik; K J Schenning; L R Clark; M A Sager; S C Johnson; B P Hermann; K J Hogan Journal: Anaesthesia Date: 2018-02-21 Impact factor: 6.955
Authors: José L Molinuevo; Laura A Rabin; Rebecca Amariglio; Rachel Buckley; Bruno Dubois; Kathryn A Ellis; Michael Ewers; Harald Hampel; Stefan Klöppel; Lorena Rami; Barry Reisberg; Andrew J Saykin; Sietske Sikkes; Colette M Smart; Beth E Snitz; Reisa Sperling; Wiesje M van der Flier; Michael Wagner; Frank Jessen Journal: Alzheimers Dement Date: 2016-11-05 Impact factor: 21.566